Endpoints News Feb 23, 2026 Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial Original